Our research group studies the implication of the serotonergic and cannabinoid systems, and the neurogenic and neuroplastic processes in the CNS to understand the etiopathogeny of neuropsychiatric disorders and the mechanism of action of the CNS-acting drugs. Specially, we focus in the study of pharmacological targets to develop new fast acting antidepressant drugs. Several methodological approaches are used: molecular, biochemical, cellular, morphological, pharmacology assays, animal models of psychiatric disorders as well as neuronal progenitors and brain organotopic cultures.